Exelixis (EXEL) in Focus: Stock Moves 7.7% Higher
Exelixis, Inc. EXEL was a big mover last session, as the company saw its shares rise nearly 8% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This reverses the recent trend for the company—as the stock is now down 14.7% in the past one-month time frame.
The Zacks Consensus Estimate for the current quarter has moved lower over the past few weeks, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward, to see if this recent move higher can last.
Exelixis currently has a Zacks Rank #4 (Sell) while its Earnings ESP is positive.
Exelixis, Inc. Price
Exelixis, Inc. Price | Exelixis, Inc. Quote
A better-ranked stock in the Medical sector is Biohaven Pharmaceutical Holding Company Ltd. BHVN, which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is EXEL going up? Or down? Predict to see what others think: Up or Down
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Exelixis, Inc. (EXEL) : Free Stock Analysis Report
BIOHAVEN PHARM (BHVN) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
